SecurityGSB / GlobalSCAPE, Inc. (37940G109)
Institutional Owners39 (1 N-Q Owners)
Institutional Shares8,583,893 - 39.79% (ex. N-Q)
Common Shares Outstanding21,571,831 shares (as of 2017-03-31)
Institutional Value$ 21,891,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

GlobalSCAPE, Inc. (AMEX:GSB) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8,583,893 shares. Largest shareholders include Fondren Management LP, Radoff Bradley Louis, Renaissance Technologies LLC, Polar Asset Management Partners Inc., Wellington Trust Co NA, Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio, Vanguard Group Inc, Bard Associates Inc, Dimensional Fund Advisors Lp, and Perritt Capital Management Inc.
GlobalSCAPE, Inc. (AMEX:GSB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-09 13F-HR BlackRock Inc. 40,656 40,172 -1.19 144 147 2.08
2018-05-10 13F-HR SEIZERT CAPITAL PARTNERS, LLC 136,290 502
2018-05-09 13F-HR IFP Advisors, Inc 100 100 0.00 0 0
2018-02-08 SC 13G/A Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 1,828,938 625,257 -65.81
2018-05-15 13F-HR Fondren Management LP 810,000 1,674,417 106.72 2,876 6,162 114.26
2018-05-14 13F-HR Roble, Belko & Company, Inc 50 50 0.00 0 0
2018-05-14 13F-HR Virtu Financial LLC 16,966 0 -100.00 60 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 45 74 64.44 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 0 622 0 2
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2 0 -100.00 0 0
2018-05-15 13F-HR UBS Group AG 4,014 80 -98.01 14 0 -100.00
2018-02-14 13F-HR ZPR Investment Management 72,373 0 -100.00 277 0 -100.00
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 33,982 18,704 -44.96 121 69 -42.98
2018-05-11 13F-HR Cutler Group LP 747 137 -81.66 2 0 -100.00
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 255,401 255,401 0.00 907 940 3.64
2018-05-14 13F-HR Renaissance Technologies LLC 1,028,600 1,106,100 7.53 3,652 4,070 11.45
2018-05-15 13F-HR PERRITT CAPITAL MANAGEMENT INC 200,000 200,400 0.20 710 741 4.37
2018-05-15 13F-HR DEUTSCHE BANK AG\ 131,760 127,509 -3.23 467 469 0.43
2018-04-20 13F-HR Covenant Multifamily Offices, LLC 5 0 -100.00 0 0
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 83,732 0 -100.00 321 0 -100.00
2018-05-14 13F-HR Resources Investment Advisors, Inc. 471 95 -79.83 12 2 -83.33
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 944 0 -100.00 3 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 39,288 58,296 48.38 139 215 54.68
2018-05-23 13F-HR/A Polar Asset Management Partners Inc. 525,000 814,010 55.05 1,864 2,996 60.73
2018-02-02 13F-HR Alambic Investment Management, L.P. 20,700 0 -100.00 79 0 -100.00
2018-05-15 13F-HR Wellington Management Group LLP 711,000 0 -100.00 2,524 0 -100.00
2018-02-28 N-Q Ishares Trust (see advisory)
2018-04-20 13F-HR Seacrest Wealth Management, Llc 5 5 0.00 0 0
2018-04-16 13F-HR MIDAS MANAGEMENT CORP 11,069 11,069 0.00 39 41 5.13
2018-02-08 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,630 0 -100.00 6 0 -100.00
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 23,355 15,314 -34.43 83 56 -32.53
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 29,423 29,423 0.00 104 108 3.85
2018-04-26 13F-HR SIMPLEX TRADING, LLC 0 95 0 0
2018-05-04 13F-HR Financial Management Professionals, Inc. 98 98 0.00 0 0
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 64,300 64,300 0.00 228 237 3.95
2018-05-14 13F-HR Poehling Capital Management, Llc 330 1
2018-05-10 13F-HR Spark Investment Management LLC 77,464 67,700 -12.60 274 249 -9.12
2018-04-12 13F-HR JAMES INVESTMENT RESEARCH INC 16,575 16,575 0.00 59 61 3.39
2018-01-26 13F-HR Ironwood Financial, llc 35 0 -100.00 0 0
2018-05-11 13F-HR Cutler Group LP Call 200 0 -100.00 0 0
2018-05-07 13F-HR MUFG Americas Holdings Corp 346 0 -100.00 1 0 -100.00
2018-02-08 SC 13G/A Wellington Trust Co NA 2,063,937 711,000 -65.55
2018-02-13 13F-HR GLOBEFLEX CAPITAL L P 19,009 0 -100.00 73 0 -100.00
2018-05-15 13F-HR Ativo Capital Management LLC 301,216 150,046 -50.19 1,069 552 -48.36
2018-05-14 13F-HR MORGAN STANLEY 2,350 962 -59.06 9 4 -55.56
2018-01-25 SC 13G Radoff Bradley Louis 1,300,000
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 0 9 0 1
2018-04-23 13F-HR Taylor, Cottrill, Erickson & Associates, Inc. 10,127 37
2018-05-09 13F-HR NORTHERN TRUST CORP 21,632 18,386 -15.01 77 68 -11.69
2018-05-15 13F-HR VANGUARD GROUP INC 540,760 608,744 12.57 1,920 2,240 16.67
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 275,100 176,600 -35.81 977 650 -33.47
2018-05-15 13F-HR RBF Capital, LLC 27,000 27,000 0.00 96 100 4.17
2018-05-14 13F-HR BARD ASSOCIATES INC 322,205 318,405 -1.18 1,144 1,172 2.45
2018-05-15 13F-HR HANCOCK HOLDING CO 61,433 0 -100.00 218 0 -100.00

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( GSB / GlobalSCAPE, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

BRIEF-GlobalSCAPE Updates Status Of Audit Committee Investigation

2018-03-16 reuters
* GLOBALSCAPE INC - NET INCOME FOR YEAR ENDED DEC 31, 2017 IS EXPECTED TO BE LOWER THAN COMPARABLE PERIOD IN 2016 (27-3)

Globalscape Is An Undervalued Player In The Growing MFT Market

2018-01-30 seekingalpha
Globalscape has achieved consistent operating results in recent years and the trend is expected to continue. (116-19)

The Ideal Stock Evaluation System?

2018-01-22 seekingalpha
About two and a half years ago, I had a revelation. I’d been losing money for years, choosing the wrong stocks, buying and selling them at the wrong times. But I suddenly realized that the key to success in the stock market is not just screening stocks on a few factors but instead to systematically evaluate every stock from as many angles as possible before buying it. Since I put my initial evaluation system in place around Halloween 2015, my compound annual returns have been 47%--a total growth of 135% in 27 months. (209-4)

CUSIP: 37940G109